Skip to main content

Estimado(a) Dr.(a) le invitamos a ver la infografía “Sinergia de los mecanismos complementarios entre insulina basal y análogos de GLP-1 ¿qué pacientes se pueden beneficiar de esta combinación?”

 

Infografía Novo Nordisk sobre la sinergia de los mecanismos complementarios entre insulina basal y análogos de GLP-1. Pacientes se pueden beneficiar

Para descargar la infografía haga clic aquí.

 

Referencias 

  1. Anderson SL, Trujillo JM. Basal Insulin Use With GLP-1 Receptor Agonists. Diabetes Spectr. 2016 Aug;29(3):152-60.
  2. Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018 Jul;14(7):390-403
  3. Gribble FM, Reimann F. Metabolic Messengers: glucagon-like peptide 1. Nat Metab 3. 2021;142–148.
  4. Moreira RO, Cobas R, Lopes Assis Coelho RC. Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? Diabetol Metab Syndr. 2018 Apr 3;10:26.
  5. Gough SCL, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al. Efcacy and safety of a xed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885–93
  6. Harris S, Abrahamson MJ, Ceriello A, Charpentier G, Evans M, Lehmann R, et al. Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. Drugs. 2020 Feb;80(2):147-165.
  7. Rosenstock J, Aronson R, Grunberger G, et al. Benets of LixiLan, a titratable xed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled with oral agents: The LixiLan-O randomized trial. Diabetes Care 2016;39:2026e35.
  8. American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care. 1 January 2022; 45 (1): S125–S143.

 

Material desarrollado con fines de educación médica continua.

Material exclusivo para profesionales de la salud.

La información aquí presentada es opinión del ponente.

Código interno de aprobación: MX22XUM00023.

Leave a Reply